



Original Article

Evaluating the effects of empagliflozin in preventing myocardial injury in patients undergoing percutaneous coronary intervention: A double-blind, randomized clinical trial

Hossein Behzad¹, Sina Mashayekhi², Hila Asham¹, Parvin Sarbakhsh³, Taher Entezari-Maleki^{1,2*}

¹Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

²Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

³Department Research Center, Faculty of Public Health, Tabriz University of Medical Sciences, Tabriz, Iran

Article info

Article History:

Received: February 12, 2024

Accepted: May 24, 2024

Published: June 25, 2024

*Corresponding Author:

Taher Entezari-Maleki,
Email: tentezari@gmail.com
entezarim@tbzmed.ac.ir

Abstract

Introduction: Percutaneous Coronary Intervention (PCI) is a fundamental procedure for coronary artery disease management, yet the risk of adverse events such as periprocedural myocardial injury (PMI) persists. This double-blind, randomized clinical trial aims to assess the efficacy of empagliflozin in preventing myocardial injury during PCI procedure.

Methods: A total of 90 patients were randomly assigned to two groups A and B; Group A as the intervention group received empagliflozin 25 mg 24 hours before and empagliflozin 10 mg 1-2 hours before coronary intervention and group B as the control group received placebo at similar intervals. The primary outcome involved comparing baseline, 8-hour, and 24-hour cTnI and baseline and 24-hour hs-CRP levels after PCI in both groups to measure the incidence of periprocedural myocardial injury (PMI) and anti-inflammatory effects of empagliflozin.

Results: Baseline cTnI levels with $P=0.955$, 8 hours after PCI with $P=0.469$, and 24 hours after the intervention with $P=0.980$ were not statistically different in the two groups. Baseline levels of hs-CRP in both intervention and control groups were not statistically significantly different ($P=0.982$). Also, there was no statistically significant difference in hs-CRP levels 24 hours after PCI in two groups ($P=0.198$). Finally, the results showed that MACEs did not occur in any of the groups.

Conclusion: The results of this trial could not express the advantages of acute pretreatment with empagliflozin in preventing PCI-related myocardial injury.

Keywords: Empagliflozin, Percutaneous coronary intervention, Periprocedural myocardial injury, cTnI, hs-CRP

Introduction

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, with myocardial infarction (MI) representing a significant contributor to this global burden.¹ Percutaneous coronary intervention (PCI), a widely employed revascularization procedure, has dramatically improved outcomes in patients with coronary artery disease (CAD).² However, despite its effectiveness, PCI can provoke myocardial damage, termed periprocedural myocardial injury (PMI), which may ultimately lead to adverse clinical outcomes. PMI has been linked to an increased risk of future major cardiovascular events and can contribute to a poorer prognosis for patients.^{3,4}

Empagliflozin, a sodium-glucose cotransporter 2 inhibitors (SGLT2-I) initially developed for managing type 2 diabetes mellitus (T2DM), has recently garnered

significant attention for its potential cardiovascular benefits beyond glycemic control.⁵ Clinical trials such as the EMPA-REG outcome trial have remarkably reduced cardiovascular mortality, heart failure hospitalization, and adverse cardiac events in patients with T2DM receiving empagliflozin. These findings have sparked interest in exploring empagliflozin's utility in the PCI context to mitigate PMI and improve clinical outcomes.^{6,7}

The pathophysiology of PMI is multifaceted, involving ischemia-reperfusion injury, inflammation, oxidative stress, and endothelial dysfunction.⁸ Empagliflozin has demonstrated pleiotropic effects that extend beyond glucose lowering. It exerts its cardio protective effects by modulating various mechanisms, including natriuresis, diuresis, and reductions in blood pressure, arterial stiffness, and intravascular volume.⁹ Additionally, empagliflozin has been shown to enhance myocardial energetics, reduce



myocardial fibrosis, and improve endothelial function, all of which may play a role in protecting against PMI.¹⁰

Despite these promising preclinical and clinical findings, there remains a paucity of research investigating the specific impact of empagliflozin on PMI in patients undergoing PCI. Given the potential benefits of empagliflozin on cardiac function and its favorable safety profile, it is imperative to explore whether its administration before or after PCI can effectively reduce PMI and improve post-procedural outcomes.^{11,12} Therefore, the present study aims to evaluate the effects of empagliflozin in preventing myocardial injury in patients undergoing PCI.

Materials and Methods

The present study was conducted prospectively, randomly, and in a double-blind clinical trial at the Shahid Madani Heart Center, the largest cardiovascular center in northwestern Iran, with a sample size of 90 patients (45 individuals in each group).

Inclusion and exclusion criteria

The inclusion criteria for this study included ischemic heart patients aged 18 to 80 years old who were candidates for elective PCI, including angioplasty with balloon and stent placement. Also, the exclusion criteria for this study included patients who met the following criteria: elevated levels beyond the reference range of cardiac troponin I (cTnI) and hs-CRP before PCI, acute myocardial infarction or a history of myocardial infarction, open-heart surgery within the last 3 months, unsuccessful PCI, patients with kidney dysfunction (eGFR < 30 ml/min), patients undergoing dialysis, patients in cardiogenic shock, severe infections, cancer, liver failure (Child Pugh score > 6), uncontrolled autoimmune and inflammatory diseases, pregnancy and lactation, a history of serious hypersensitivity reactions to empagliflozin or any component of the formulation, type 1 diabetes mellitus, diabetic ketoacidosis, and patients who did not provide informed consent.

Trial procedures

Participants were divided into two groups, A and B, using GraphPad Prism software and a 1:1 randomization method. Group A served as the intervention group and received empagliflozin 25 mg 24 hours before and empagliflozin 10 mg 1-2 hours before coronary intervention. Group B, on the other hand, served as the control group and received a placebo 24 hours before and 1-2 hours before coronary intervention.

Selection of patient

The total number of patients included in the evaluation was 110, five patients due to high baseline levels of cTnI, four patients due to a history of infarction or open-heart surgery in the last three months, two patients due to renal failure, and one patient due to type 1 diabetes mellitus,

were excluded from the study. After the intervention and in the follow-up phase, the data of eight patients (four patients due to unsuccessful PCI and four patients with simultaneous involvement of three vessels) were excluded. Finally, 90 patients including 45 patients in the intervention group and 45 patients in the control group were included in the analysis. The study process is shown in [Figure 1](#).

The study was conducted as a double-blind trial, and participants and the researcher were unaware of the group assignments, which were coded as A and B. All participating patients followed standard preparations before angioplasty, including the consumption of aspirin 325 mg, clopidogrel 300 mg (4 tablets of 75 mg each), and intravenous heparin (with a goal of achieving a clotting time of 250-350 seconds) uniformly. Additionally, both groups received 100 ± 20 cc of the contrast agent iodixanol during the PCI procedure. To prevent contrast-induced nephropathy, hydration with isotonic saline (1ml/kg/h) was administered from 6-12 hours before the procedure until 6-12 hours after. All participants underwent PCI by the same standardized international team that was unaware of the individual group assignments.

During a one-month follow-up period, all patients were assessed for major adverse cardiac events (MACEs), including death, Q-wave myocardial infarction, revascularization of the target vessel, and ischemic stroke, as secondary outcome.

Patient demographic information, including gender, age, weight, height, BMI, medication history, medical history, laboratory data, and a positive family history of cardiovascular diseases, were recorded on data collection forms.

Blood sampling

Blood sampling was conducted according to the Fourth Universal Definition of Myocardial Infarction (UDMI). Baseline levels of the cardiac biomarker cTnI were measured before PCI and before empagliflozin administration (25 mg and placebo). Measurements were also taken at 8 and 24 hours after PCI. Additionally, baseline hs-CRP levels and 24 hours post-intervention were measured and recorded to evaluate inflammation.

The level of serum CRP was measured using hs-CRP immunoassay test kits (Aptec Diagnostics, 9100 Sint-Niklaas, Belgium; 9100 Sint-Niklaas, Belgium). The measurement range is 0 to 14 mg/dL with a detection limit of 0.013 mg/dL. The risk of cardiovascular diseases will be determined based on the kits reference values: less than 0.10 mg/dL as low-risk, 0.10 to 0.30 mg/dL as intermediate-risk, and greater than 0.30 mg/dL as high-risk. Serum troponin level was determined using an ELISA sandwich method (Monobind Inc, USA) with a detection limit of 0.1 ng/ml and upper limit normal of 1.2 ng/ml.

Study Outcomes

The primary outcome involved comparing baseline,




Figure 1. Patients' selection and randomization

8-hour, and 24-hour cTnI levels after PCI in both groups to assess the occurrence of PMI. Furthermore, a comparison of baseline and 24-hour hs-CRP levels in the groups was conducted to investigate the anti-inflammatory effects of empagliflozin. The secondary outcome was the incidence of major cardiac events (death, Q-wave myocardial infarction, revascularization of the target vessel, and ischemic stroke) during a one-month follow-up after PCI.

Sample size and post-hoc power calculation

Due to the lack of similar studies, the present study's sample size determined as a pilot subject of 45 individuals in two groups based. The post-hoc power calculation was also performed with the sample size of 90, two equal groups, three times of measurements, and $\alpha=0.05$ using G*Power 3.1.9.2. The power ($1-\beta$ error) for cTnI test with partial η^2 of 0.057 and calculated effect size (F) of 0.245 was calculated 0.80.

Statistical analysis

Data were analyzed in SPSS 26 software. The normal distribution of the data was evaluated with the Kolmogorov-Smirnov test, and quantitative variables were evaluated with the Chi-square test or Fisher exact test. Repeated measure ANOVA was used for within-between comparisons by Bonferroni adjustment. Continuous variable comparison between two groups was performed using independent t-test method or Mann-Whitney U if

appropriated. P-values of 0.05 or below were considered significant for all outcomes.

Results

The intervention group included 25 women (55.5%) and 20 men (44.5%), and the control group included 19 women (42.2%) and 26 men (57.8%). The mean \pm SD for the age of the patients in the intervention and control groups was 59.2 ± 9 and 59.4 ± 9.3 , respectively, which indicates the prevalence of ischemic heart diseases in the elderly. Most of the targeted stent vessels were left anterior descending artery (LAD), with 49% and 44.4% in intervention and control groups, respectively. About one-third of patients were one-vessel disease [$n=17$ (37.7%) vs. $n=15$ (33.3%)] in the intervention and the control groups respectively ($P=0.66$). The mean \pm SD number of stents per patient was 1.49 ± 0.7 in the intervention group and was 1.35 ± 0.6 in the control group. All patients received drug eluted stents. Basic demographic and clinical information of the patients has no significant difference ($P<0.05$) (Table 1).

Baseline cTnI levels with $P=0.955$, 8 hours after PCI with $P=0.469$, and 24 hours after the intervention with $P=0.980$ were not statistically different in the two groups (Table 2), (Figure 2).

Baseline levels of hs-CRP in both intervention and control groups were not statistically significantly different ($P=0.982$). Also, there was no statistically significant difference in hs-CRP levels 24 hours after PCI in the two

groups ($P=0.198$) (Table 3), (Figure 2). Finally, the results showed that MACEs did not occur in any of the groups.

We also did not detect any significant drug-related adverse outcome such as diabetic ketoacidosis, hypoglycemia, severe infection and severe hypotension, in both study groups.

Discussion

Empagliflozin has shown anti-inflammatory and anti-fibrotic effects in preclinical studies. These properties may help reduce inflammation and fibrosis in the myocardium, potentially protecting it from further damage during and after PCI.¹³

Here, we evaluated the effects of empagliflozin in preventing myocardial damage in patients undergoing

Table 1. Demographic and clinical information of the subjects in both groups

Variable	Intervention (n=45)	control (n=45)	p-value
Age (years)	59.2 ± 9	59.4 ± 9.3	0.93
Gender			
Female	25 (55.5%)	19 (42.2%)	0.2
Man	20 (44.5%)	26 (57.8%)	
Weight (kg)	76.53 ± 13.9	79.57 ± 9.6	0.23
Height (m)	1.66 ± 0.06	1.66 ± 0.06	0.52
BMI(kg/m ²)	27.65 ± 4.4	28.59 ± 3.3	0.264
Smoking	17 (37.7%)	18 (40%)	0.829
DM	6 (13.3%)	10 (22.2%)	0.27
HTN	33 (73.3%)	34 (75.5%)	0.8
Dyslipidemia	45 (100%)	45 (100%)	1
History of other diseases	14 (31.1%)	11 (24.4%)	0.48
Family history of heart disease	17 (37.7%)	17 (37.7%)	1
History of open-heart surgery	0	0	1
PCI history	0	0	1
Use of cardiovascular drugs	43 (95.5%)	45 (100%)	0.494
Use of antidiabetic drugs	6 (13.3%)	10 (22.2%)	0.27
Use of dyslipidemia drugs	38 (84.4%)	41 (91.1%)	0.334
Use of other medication	32 (71.1%)	31 (68.8%)	0.81
LAD	22 (49%)	20 (44.4%)	0.673
RCA	11 (24.4%)	13 (28.8%)	0.634
LCX	8 (17.7%)	10 (22.2%)	0.598
OM	7(15.5%)	6 (13.3%)	0.764
Other vessels	8 (17.7%)	7 (15.5%)	0.777
One-vessel disease	17 (37.7%)	15 (33.3%)	0.660
Two-vessel disease	12 (26.6%)	10 (22.2%)	0.231
Three-vessel disease	5 (11.1%)	7 (15.5%)	0.535
Total stents diameter (mm), mean ± SD	2.8 ± 0.47	2.9 ± 0.5	0.210
Total stents length (mm), mean ± SD	21 ± 6.4	19.5 ± 5.3	0.205
Number of stents per patient, mean ± SD	1.49 ± 0.7	1.35 ± 0.6	0.278

Data has been presented as N (%), mean ± SD or median (IQR) which is appropriate.

BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; LAD, left anterior descending artery; LCX, left circumflex artery; OM, obtuse marginal artery; RCA, right coronary artery

PCI. The results of the study revealed that levels of hs-CRP and troponin I in both intervention and control groups were not significantly different.

Preventing myocardial damage during PCI is a multifaceted challenge, and a comprehensive pharmacological approach involves not only cardiovascular index drugs but also various agents from different therapeutic categories. While antiplatelet medications, statins, and vasodilators continue to be essential, researching more recent medications, like anti-inflammatory medications and antioxidants, presents promising opportunities for outcome improvement.^{14,15} Newer drugs like ticagrelor and prasugrel offer greater platelet inhibition over the traditional dual antiplatelet therapy (aspirin plus a P₂Y₁₂ receptor inhibitor), lowering the risk of thrombotic events during PCI.¹⁶ In high-risk PCI situations, medications such as eptifibatid and abciximab work in conjunction with antiplatelet treatment to prevent platelet aggregation.¹⁷ Beyond lowering cholesterol, statins like atorvastatin and rosuvastatin have pleiotropic effects. They are capable of lowering peri-procedural myocardial damage due to their anti-inflammatory and anti-thrombotic characteristics.¹⁸ The findings of two clinical trial studies showed that a single high dose of rosuvastatin prior to PCI reduces periprocedural myocardial injury in patients with acute coronary syndrome.^{19,20} Also, two clinical trial studies revealed that a single, high-loading dose of atorvastatin reduces the incidence of periprocedural myocardial infarction in elective PCI.^{21,22} In the study of Park et al by continuous intravenous administration of landiolol as a beta-blocker, a very significant reduction in the occurrence of periprocedural myocardial ischemia was observed.²³

Calcium channel blockers (CCBs) are among other categories of drugs whose intracoronary injection has been investigated in the incidence of periprocedural myocardial ischemia. Despite features such as the reduction of creatine phosphokinase (CPK) during PCI, the beneficial effects on vascular tone and coronary endothelial function are still not completely clear. In the study conducted by Arora et al on 193 patients with chronic stable angina, the intracoronary administration of nicardipine could not reduce the increase of the troponin after elective PCI.²⁴

The results of a meta-analysis study (2021) reported that

Table 2. Mean Troponin I Level at Baseline and 8 and 24 Hours After PCI

Troponin I level	Intervention (n=45)	Control (n=45)	P-value
Baseline	0.11 ± 0.05	0.1 ± 0.02	0.955
8 hours after PCI	0.19 ± 0.39	0.14 ± 0.07	0.469
24 hours after PCI	0.2 ± 0.26	0.18 ± 0.26	0.980

Table 3. Mean hs-CRP Level at Baseline and 24 Hours After PCI

hs-CRP level	Intervention (n=45)	Control (n=45)	P-value
Baseline	8.2 ± 5.9	8.4 ± 6.3	0.982
24 hours after PCI	11.8 ± 7.1	9.7 ± 6.1	0.198




Figure 2. A. changes in troponin I after PCI at baseline, 8 and 24 h. B. changes in hs-CRP after PCI at baseline and 24 h

the administration of pre-procedure trimetazidine may have a role in reducing periprocedural myocardial injury in patients with CAD undergoing PCI.²⁵ Shah et al study (2020) showed that acute preprocedural administration of colchicine reduced the increase in interleukin-6 and hs-CRP concentrations after PCI when compared with placebo but did not lower the risk of PCI-related myocardial injury.²⁶

Aslanabadi et al (2018) conducted a randomized, controlled trial study to evaluate the effect of vitamin D in preventing cardiac injury in patients undergoing elective PCI. The results of this study were in line with the results of the current research and showed a non significant effect of vitamin D on cardiac biomarkers; however, the mean difference in CK-MB between 8 and 24 hours and the mean difference in hs-CRP were significantly in favor of the vitamin D group.²⁷

The findings of a pilot randomized clinical trial (2021) did not support the potential cardio-protective benefits of allopurinol administration on decreasing myocardial injury following non-ST elevation myocardial infarction.²⁸ The effects of SGLT2-Is on primary PCI among patients with acute coronary syndrome (ACS) were evaluated through previous studies. The results of the Adel et al study (2022) showed that the empagliflozin and placebo groups were not significantly different compared to the standard treatment results in terms of incidence of death, hospitalization due to unstable angina, and coronary revascularization after treatment.²⁹ Compared to our study, in this review diabetic patients were randomly assigned to receive empagliflozin (10 mg once daily) or placebo at similar doses for 6 months after primary PCI, but in our study patients in the intervention group received two doses of this drug after elective PCI. The results of another study revealed that diabetic individuals with acute myocardial infarction (AMI) who underwent primary PCI and were treated with SGLT-Is had lower CRP levels on admission compared to those in the control group, with a statistically significant difference ($P < 0.001$). This observational study also evaluated the level of CRP after 24 hours and at discharge (a median of

5 days), showing significant beneficial effects of SGLT-Is in lowering CRP levels ($P = 0.01$ for both).³⁰ However, our study did not show a significant effect of empagliflozin among individuals undergoing elective PCI.

This randomized-double-blinded clinical trial is the first of its kind evaluated the effects of empagliflozin in preventing PCI-related myocardial injury and this study may be base for direction of future large studies. This study may also have some limitations, such as; small sample size, single center, and short study duration. We also couldn't measure SYNTAX score in both groups.

Conclusion

The present study couldn't support the potential benefit of empagliflozin on cTnI and hs-CRP levels following elective PCI. Further studies are recommended to show the effects of empagliflozin in prevention of myocardial injury following elective PCI.

Acknowledgments

The authors thank the personal of Cardiovascular Research Center of Shahid Madani Heart Center of Tabriz University of Medical Sciences for support of the study.

Authors' Contribution

Conceptualization: Taher Entezari-Maleki.

Data Curation: Hossein Behzad.

Formal analysis: Taher Entezari-Maleki, Parvin Sarbakhsh.

Funding acquisition: Taher Entezari-Maleki.

Investigation: Hossein Behzad.

Methodology: Taher Entezari-Maleki.

Project administration: Sina Mashayekhi.

Resources: Sina Mashayekhi.

Supervision: Taher Entezari-Maleki.

Validation: Sina Mashayekhi.

Visualization: Hila Asham.

Writing—original draft: Hossein Behzad.

Writing—review & editing: Hila Asham.

Competing Interests

The authors declare that they have no conflict of interest.

Ethical Approval

This study received approval from the Ethics Committee of Tabriz University of Medical Sciences with the ethics code

IR.TBZMED.REC.1401.673. Furthermore, the current research was registered at the Iranian Registry of Clinical Trials with the code IRCT20221102056378N1.

Funding

This work is a part of Ph.D. thesis and was granted by the Faculty of Pharmacy, Tabriz, under grant number 69750.

References

- Jayaraj JC, Davatyan K, Subramanian SS, Priya J. Epidemiology of myocardial infarction. In: Pamukcu B, ed. *Myocardial Infarction*. Rijeka: IntechOpen; 2019. doi: [10.5772/intechopen.74768](https://doi.org/10.5772/intechopen.74768).
- Choi KH, Song YB, Lee JM, Lee SY, Park TK, Yang JH, et al. Impact of intravascular ultrasound-guided percutaneous coronary intervention on long-term clinical outcomes in patients undergoing complex procedures. *JACC Cardiovasc Interv*. 2019;12(7):607-20. doi: [10.1016/j.jcin.2019.01.227](https://doi.org/10.1016/j.jcin.2019.01.227).
- Ferrante A, Guedeney P, Silvain J, Zeitouni M, Collet JP. Mechanisms and definitions of periprocedural myocardial infarction in the era of modern revascularization. *Rev Cardiovasc Med*. 2022;23(10):351. doi: [10.31083/j.rcm2310351](https://doi.org/10.31083/j.rcm2310351).
- Gregson J, Stone GW, Ben-Yehuda O, Redfors B, Kandzari DE, Morice MC, et al. Implications of alternative definitions of peri-procedural myocardial infarction after coronary revascularization. *J Am Coll Cardiol*. 2020;76(14):1609-21. doi: [10.1016/j.jacc.2020.08.016](https://doi.org/10.1016/j.jacc.2020.08.016).
- Gallwitz B. The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors - real-world data. *Eur Endocrinol*. 2018;14(1):17-23. doi: [10.17925/ee.2018.14.1.17](https://doi.org/10.17925/ee.2018.14.1.17).
- Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. *Eur Heart J*. 2016;37(19):1526-34. doi: [10.1093/eurheartj/ehv728](https://doi.org/10.1093/eurheartj/ehv728).
- Lee HF, Chan YH, Chuang C, Li PR, Yeh YH, Hsiao FC, et al. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors. *Eur Heart J Cardiovasc Pharmacother*. 2023;9(4):301-10. doi: [10.1093/ehjcvp/pvad004](https://doi.org/10.1093/ehjcvp/pvad004).
- Zhang PX, Zhang HX, Hou DL, Xiao ZC, Zhou CY. Cardioprotection of rosuvastatin pre-conditioning on myocardial ischemia/reperfusion injury in a rat model. *Braz Arch Biol Technol*. 2019;62:e19190055. doi: [10.1590/1678-4324-2019190055](https://doi.org/10.1590/1678-4324-2019190055).
- Kowalska K, Walczak J, Femplak J, Mlynarska E, Franczyk B, Rysz J. Empagliflozin-a new chance for patients with chronic heart failure. *Pharmaceuticals (Basel)*. 2021;15(1):47. doi: [10.3390/ph15010047](https://doi.org/10.3390/ph15010047).
- Shiraki A, Oyama JI, Shimizu T, Nakajima T, Yokota T, Node K. Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure. *Eur J Pharmacol*. 2022;931:175194. doi: [10.1016/j.ejphar.2022.175194](https://doi.org/10.1016/j.ejphar.2022.175194).
- Nusca A, Piccirillo F, Bernardini F, De Filippis A, Coletti F, Mangiacapra F, et al. Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic agents? A comprehensive review of basic science and clinical data. *Int J Mol Sci*. 2022;23(13):7261. doi: [10.3390/ijms23137261](https://doi.org/10.3390/ijms23137261).
- Gu J, Wang Y, Wang CQ, Zhang JF. The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention. *Eur J Intern Med*. 2023;112:62-9. doi: [10.1016/j.ejim.2023.03.019](https://doi.org/10.1016/j.ejim.2023.03.019).
- Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. *Diabetol Metab Syndr*. 2016;8:45. doi: [10.1186/s13098-016-0169-x](https://doi.org/10.1186/s13098-016-0169-x).
- Cuculi F, Lim CC, Banning AP. Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented? *Heart*. 2010;96(10):736-40. doi: [10.1136/hrt.2009.186189](https://doi.org/10.1136/hrt.2009.186189).
- Babu GG, Walker JM, Yellon DM, Hausenloy DJ. Periprocedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. *Eur Heart J*. 2011;32(1):23-31. doi: [10.1093/eurheartj/ehq393](https://doi.org/10.1093/eurheartj/ehq393).
- Kim HS, Kang J, Hwang D, Han JK, Yang HM, Kang HJ, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. *Lancet*. 2020;396(10257):1079-89. doi: [10.1016/s0140-6736\(20\)31791-8](https://doi.org/10.1016/s0140-6736(20)31791-8).
- Sharifi-Rad J, Sharopov F, Ezzat SM, Zam W, Ademiluyi AO, Oyeniran OH, et al. An updated review on glycoprotein IIb/IIIa inhibitors as antiplatelet agents: basic and clinical perspectives. *High Blood Press Cardiovasc Prev*. 2023;30(2):93-107. doi: [10.1007/s40292-023-00562-9](https://doi.org/10.1007/s40292-023-00562-9).
- Lampropoulos K, Megalou A, Bazoukis G, Tse G, Manolis A. Pre-loading therapy with statins in patients with angina and acute coronary syndromes undergoing PCI. *J Interv Cardiol*. 2017;30(6):507-13. doi: [10.1111/joic.12421](https://doi.org/10.1111/joic.12421).
- Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. *Int J Cardiol*. 2009;137(3):246-51. doi: [10.1016/j.ijcard.2008.06.055](https://doi.org/10.1016/j.ijcard.2008.06.055).
- Cay S, Cagirci G, Sen N, Balbay Y, Durmaz T, Aydogdu S. Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. *Cardiovasc Drugs Ther*. 2010;24(1):41-7. doi: [10.1007/s10557-010-6224-1](https://doi.org/10.1007/s10557-010-6224-1).
- Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. *J Am Coll Cardiol*. 2009;54(6):558-65. doi: [10.1016/j.jacc.2009.05.028](https://doi.org/10.1016/j.jacc.2009.05.028).
- Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. *J Am Coll Cardiol*. 2009;54(23):2157-63. doi: [10.1016/j.jacc.2009.07.005](https://doi.org/10.1016/j.jacc.2009.07.005).
- Park H, Otani H, Noda T, Sato D, Okazaki T, Ueyama T, et al. Intracoronary followed by intravenous administration of the short-acting β -blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention. *Int J Cardiol*. 2013;167(4):1547-51. doi: [10.1016/j.ijcard.2012.04.096](https://doi.org/10.1016/j.ijcard.2012.04.096).
- Arora S, Alfayoumi F, Khawaja AT, Dua A, Srinivasan V, Gradman AH. Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. *Clin Cardiol*. 2009;32(6):315-20. doi: [10.1002/clc.20580](https://doi.org/10.1002/clc.20580).
- Wang C, Chen W, Yu M, Yang P. Efficacy of trimetazidine

- in limiting periprocedural myocardial injury in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. *Angiology*. 2021;72(6):511-23. doi: [10.1177/0003319720987745](https://doi.org/10.1177/0003319720987745).
26. Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. *Circ Cardiovasc Interv*. 2020;13(4):e008717. doi: [10.1161/circinterventions.119.008717](https://doi.org/10.1161/circinterventions.119.008717).
 27. Aslanabadi N, Jafaripor I, Sadeghi S, Hamishehkar H, Ghaffari S, Toluey M, et al. Effect of vitamin D in the prevention of myocardial injury following elective percutaneous coronary intervention: a pilot randomized clinical trial. *J Clin Pharmacol*. 2018;58(2):144-51. doi: [10.1002/jcph.989](https://doi.org/10.1002/jcph.989).
 28. Khiali S, Sarbakhsh P, Mashayekhi S, Mohamadrezapour E, Dousti S, Entezari-Maleki T. The effects of allopurinol on levels of cardiac troponin following non-ST elevation myocardial infarction: a pilot randomized clinical trial. *Pharm Sci*. 2021;27(4):560-7. doi: [10.34172/ps.2021.14](https://doi.org/10.34172/ps.2021.14).
 29. Adel SM, Jorfi F, Mombeini H, Rashidi H, Fazeli S. Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention. *Saudi Med J*. 2022;43(5):458-64. doi: [10.15537/smj.2022.43.5.20220018](https://doi.org/10.15537/smj.2022.43.5.20220018).
 30. Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. *Cardiovasc Diabetol*. 2022;21(1):77. doi: [10.1186/s12933-022-01506-8](https://doi.org/10.1186/s12933-022-01506-8).